Search Results | DrugBank Online

Displaying drugs 11101 - 11125 of 12844 in total

KUR-113

KUR-113 is an investigational fibrin-based agent containing an N-terminally modified parathyroid hormone fragment. It is being investigated as a bioactive bone graft substitute.

Investigational

AVB-101

AVB-101 is a recombinant AAV9 vector encoding the human progranulin (PGRN) gene.

Investigational

NFS-02

NFS-02 is a recombinant adeno-associated virus serotype 2 containing human mitochondrial ND1 codon optimized gene (rAAV2-ND1).

Investigational

ASC-618

ASC-618 is a recombinant adeno-associated virus serotype 8 (rAAV2/8) vector expressing bioengineered B domain deleted liver-codon-optimized human factor VIII.

Investigational

Denecimig

Delpacibart is a humanized, bispecific, bivalent monoclonal antibody against coagulation factor 9.

Investigational

RC118

RC118 is an antibody-drug conjugate that consists of a recombinant humanized IgG1 anti-Claudin18.2 monoclonal antibody conjugated to MMAE.

Investigational

AGTC-402

AGTC-402 is a recombinant adeno-associated virus vector expressing the cyclic nucleotide gated channel alpha subunit (CNGA3).

Investigational

Recombinant surfactant protein D

Investigational

SCIB1 is an investigational cancer vaccine being developed by Scancell Ltd. It is being investigated for the treatment of melanoma. It consists of plasmid DNA molecules that express a modified antibody in human cells, working to stimulate the patient's T cells to have a stronger reaction against melanoma cells.

Investigational

Mycobacterium vaccae

Investigational

AVB-001

AVB-001 is an encapsulated, engineered human ARPE-19 cell line that constitutively expresses the native human IL-2 cytokine

Investigational

EXT608

EXT608 is a long-acting PTH derivative under investigation for the treatment of hyperparathyroidism.

Investigational

ALT-P1

ALT-P1 is a long-acting recombinant human growth hormone fused to an alpha1-antitrypsin variant. It is under investigation for the treatment of growth hormone deficiency.

Investigational

TRK-250

TRK-250 is a small interfering RNA agent that targets human transforming growth factor-beta 1 (TGF-β1) messenger RNA.

Investigational

ISP-001

ISP-001 consists of sleeping beauty transposon-engineered autologous plasmablasts for expression and delivery of alpha-L-iduronidase.

Investigational

RAG-17

RAG-17 is a siRNA oligonucleotide designed to target and knockdown the expression of superoxide dismutase (SOD).

Investigational

NTLA-2001

NTLA-2001 is a clustered regularly interspaced short palindromic repeats CRISPR/ Cas9-based gene therapy consisting of a single guide RNA targeting the human TTR gene and a messenger RNA encoding Cas9.

Investigational